Redefining How
—and Where—
Cancer is Detected
PanGIA Biotech is transforming diagnostics with a globally scalable, AI/ML-powered, urine-based true liquid biopsy—designed to catch cancer early, with greater access.
Meeting Global Demand
with Non-Invasive Solutions
With our first assay already in use internationally and additional assays in development, we’re positioned to meet global demand in a $249B+ oncology diagnostics market³.
A True Liquid Biopsy. A Scalable Platform.
A Market Ready for Change.
Proven performance in detecting high-grade prostate cancer using a simple urine sample
The PanGIA Analysis System (PAS) is the diagnostic foundation behind our true liquid biopsy approach, enabling scalable, non-invasive detection across multiple biofluids.
The PanGIA Prostate Assay delivers fast, actionable results—without blood draws, sequencing, or centralized lab processing.
Assigned a proprietary lab code (PLA) by the American Medical Association, the test is already gaining traction in clinical settings.
Built on three issued patents and validated through IRB-approved, multi-site studies, our approach integrates biomolecular analysis and AI/ML to streamline early detection and support clinical decision-making. ¹ ² ⁵
Data from our most recent validation study will be presented at the 2025 ASCO Annual Meeting (Poster Title: Publication Pending).
With 10+ additional cancers in development and regulatory milestones underway, PanGIA is unlocking scalable access to earlier detection.
Peer-Reviewed Foundation.
Real-World Application.
Scientifically Vetted. Clinically Relevant.
PanGIA Biotech’s technology has been recognized in The Analyst, published by the Royal Society of Chemistry, for its diagnostic potential.⁴
The foundational study behind our licensed NUTEC Slide technology introduced a novel method for detecting biomolecular patterns using colorimetric reactions, validated across diverse sample types.
The PanGIA Platform eliminates the need for complex sequencing or centralized labs, enabling scalability across various clinical settings.
Positioned for Growth.
Built for Access.
We’re pursuing a multi-channel commercialization strategy that includes provider partnerships, international expansion, and reimbursement-based access in the U.S.—with potential for data-driven insights and licensing revenue.⁵
By aligning with existing care pathways and simplifying access, PanGIA Biotech is designed to scale in both developed and emerging markets.
Meet the Team. See the Science.
Follow Our Progress.
Explore the leadership, scientific guidance, and recent milestones driving PanGIA Biotech forward.
Learn about the experts shaping our platform, clinical direction, AI/ML innovation, and commercial roadmap.
Help Shape the Future
of Early Cancer Detection
who are aligned with our mission to
redefine what’s possible in early cancer detection.
Disclaimer: This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of PanGIA Biotech. Any offering will be made only by means of a prospectus filed with the SEC.
References:
- PanGIA Biotech GH-215 Clinical Study Report, 2024.
- PanGIA Biotech Internal Data, April 2025.
- International Agency for Research on Cancer. Global Cancer Statistics. World Health Organization; 2022.
- The Analyst, Royal Society of Chemistry, 2022.
- PanGIA Executive Summary. Non-confidential. April 2025.